Reclast (Zoledronic Acid) Pediatric (Under 12) Safety: What Clinicians and Parents Need to Know

What Is Zoledronic Acid and Why Is It Used in Young Children?

Zoledronic acid is a third-generation nitrogen-containing bisphosphonate that binds hydroxyapatite in bone and inhibits osteoclast-mediated resorption by blocking the mevalonate pathway enzyme farnesyl pyrophosphate synthase. It is given as a single annual intravenous infusion rather than a daily or weekly oral tablet, which makes it appealing for children who cannot reliably take oral bisphosphonates.

In adults, the landmark HORIZON-PFT trial (N=7,736) demonstrated a 70% relative risk reduction in morphometric vertebral fractures with annual zoledronic acid 5 mg IV compared with placebo over 3 years, published in the New England Journal of Medicine in 2007 [1]. That trial enrolled postmenopausal women and established the evidence base the FDA used to approve Reclast for adult osteoporosis. Children under 12 were not included.

Off-label pediatric use is driven by several orphan-disease scenarios where bone fragility is severe and oral agents are impractical. The most studied indication is osteogenesis imperfecta (OI), a genetic collagen disorder associated with recurrent fractures and progressive deformity. Secondary osteoporosis from prolonged glucocorticoid therapy, immobilization osteoporosis in children with cerebral palsy, and hypophosphatasia-associated fragility are additional contexts where pediatric bone specialists may reach for IV bisphosphonates.

Pamidronate (another IV bisphosphonate) has historically been the standard of care in OI because it carries longer pediatric safety data going back to the mid-1990s. Zoledronic acid is increasingly used because its once-yearly schedule reduces hospital visits, a non-trivial benefit for families managing complex pediatric conditions. A 2011 randomized trial by Barros et al. (N=34, Journal of Bone and Mineral Research) directly compared zoledronic acid against pamidronate in OI children aged 3 to 17 and found comparable gains in lumbar spine bone mineral density Z-score at 12 months [2]. The zoledronic acid arm did show a higher rate of first-infusion acute-phase reactions.

What Does FDA Labeling Actually Say About Pediatric Use?

The FDA has not approved zoledronic acid (Reclast 5 mg formulation) for any pediatric indication. The prescribing information states explicitly that safety and efficacy in pediatric patients have not been established for the osteoporosis indication [3]. A separate formulation, Zometa (zoledronic acid 4 mg), carries an adult oncology indication for bone metastases and hypercalcemia of malignancy, and it too lacks a pediatric approval for skeletal fragility.

Because neither formulation carries a labeled pediatric dose, dosing guidance comes from published case series, the small randomized trials cited above, and expert consensus from organizations such as the Pediatric Endocrine Society and the International Osteoporosis Foundation. The most frequently cited weight-based approach in the literature is 0.025 to 0.05 mg/kg IV infused over at least 30 minutes, with a ceiling dose of 4 mg per infusion [2, 4]. Some centers use a flat dose of 0.05 mg/kg for children with OI and dose-reduce to 0.025 mg/kg in children with renal impairment or a history of hypocalcemia.

The FDA Amendments Act of 2007 and the Pediatric Research Equity Act require sponsors to conduct pediatric studies for certain drugs, but bisphosphonates for pediatric osteoporosis have not been subject to a Pediatric Written Request for the skeletal fragility indication as of the current labeling cycle. Clinicians prescribing off-label must document the clinical rationale, obtain informed consent that explicitly notes the absence of FDA approval, and follow institutional protocols for off-label use in minors.

What Are the Main Safety Risks in Children Under 12?

Acute-Phase Reaction

The most predictable adverse event after a first zoledronic acid infusion is an acute-phase reaction, sometimes called a flu-like reaction or post-infusion syndrome. It appears within 24 to 72 hours and includes fever (peak temperature up to 39.5 degrees Celsius in some pediatric reports), myalgia, arthralgia, headache, and fatigue. The mechanism involves a transient rise in gamma-delta T-cell cytokines, particularly tumor necrosis factor-alpha and interleukin-6.

Rates in pediatric series range from 30% to 70% for the first infusion, with the highest rates in bisphosphonate-naive patients. After the second and third annual infusions, the reaction rate drops to roughly 5 to 10% [2, 4]. Premedication with acetaminophen 15 mg/kg (max 650 mg) given 30 minutes before the infusion and continued every 6 hours for 24 hours reduces symptom severity but does not eliminate the reaction in all children. Ibuprofen 10 mg/kg may be used as an alternative if acetaminophen is insufficient, provided no contraindication exists.

Hypocalcemia

Zoledronic acid suppresses osteoclast activity acutely, which reduces calcium efflux from bone. Combined with any pre-existing vitamin D insufficiency, this can produce symptomatic hypocalcemia within 24 to 48 hours of infusion. In children, early hypocalcemia may present as perioral tingling, muscle cramps, Chvostek sign, or, in severe cases, tetany and seizures.

Pediatric studies consistently identify vitamin D deficiency (25-OH vitamin D <20 ng/mL) and inadequate dietary calcium intake as the primary modifiable risk factors [5]. The standard prevention protocol requires correcting 25-OH vitamin D to above 20 ng/mL and ensuring calcium intake meets the Dietary Reference Intake for age (1 to 000 mg/day for children ages 4 to 8; 1 to 300 mg/day for ages 9 to 13) before scheduling the infusion. Supplemental calcium carbonate or calcium citrate should be continued for at least 2 weeks post-infusion in children with OI or glucocorticoid-exposed bone, where the remodeling suppression is greatest.

Renal Toxicity

The kidney is the primary elimination organ for zoledronic acid. The drug is not metabolized hepatically; approximately 39% to 55% of an administered dose is excreted unchanged in urine within 24 hours of infusion [3]. Creatinine rises of 0.5 mg/dL or more above baseline have been observed in adults receiving the drug too rapidly or who were dehydrated at the time of infusion. In children, whose smaller body surface area and potentially lower GFR at young ages amplify exposure per unit body weight, the risk profile is proportionally elevated.

The prescribing information contraindications zoledronic acid in patients with a creatinine clearance below 35 mL/min [3]. For children under 12, most centers use the Schwartz equation to estimate GFR before each annual infusion. Children with chronic kidney disease stages 3 through 5 should not receive zoledronic acid. Adequate hydration (oral fluids or a 10 mL/kg IV saline bolus before infusion) is standard practice at centers with pediatric bone programs. Serum creatinine should be rechecked 72 hours post-infusion in children with borderline renal function at baseline.

Effects on Growing Bone and Growth Plates

This is where pediatric use diverges most sharply from adult use in terms of theoretical concern. Bisphosphonates incorporate into bone matrix and suppress osteoclast-mediated resorption for years after dosing ends, a property called the "depot effect." In growing children, normal long-bone growth requires coordinated resorption at the metaphysis by osteoclasts. Animal studies in growing rats have demonstrated that high-dose bisphosphonate exposure can produce dense metaphyseal bands, impair longitudinal bone growth, and alter growth-plate cartilage turnover [6].

In clinical pediatric OI series, the characteristic "zebra lines" (dense transverse metaphyseal bands visible on X-ray) appear after bisphosphonate therapy and reflect suppressed remodeling at the growth front. These bands have not been shown to cause clinically significant growth arrest in the doses used for OI, and height velocity data in the largest OI cohorts show normal or near-normal linear growth during treatment [4]. Still, the absence of long-term data beyond 3 to 5 years of treatment in children under 12 means that multi-year suppression of remodeling during peak skeletal growth remains an open question.

The HealthRX pediatric zoledronic acid safety checklist, reviewed by our clinical team, summarizes the pre-infusion, during-infusion, and post-infusion monitoring steps across four time windows: (1) 4 to 6 weeks before infusion for lab correction, (2) day of infusion for hydration and premedication, (3) 24 to 72 hours post-infusion for calcium and renal labs, and (4) annual reassessment for growth velocity and DXA Z-scores. This framework is intended to guide care coordination between the prescribing pediatric endocrinologist or orthopedist and the infusion center nursing team.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a well-documented adverse effect of bisphosphonate therapy in adult oncology patients receiving high cumulative doses. In the pediatric fragility-fracture setting, where doses are lower and infusion frequency is once yearly rather than monthly, ONJ has been reported only as isolated case reports. A 2014 systematic review by Hald et al. covering pediatric bisphosphonate use (all agents, all indications, N=406 patients from 26 studies) found zero confirmed ONJ cases [4]. Dental clearance before initiating therapy and avoidance of invasive dental procedures during active treatment remain prudent practice, even if absolute risk appears low in this age group.

Atypical Femoral Fracture

Atypical femoral fractures (AFF) are stress fractures of the subtrochanteric or diaphyseal femur linked to prolonged bisphosphonate-induced suppression of bone remodeling in adults. The American Society for Bone and Mineral Research task force identified an incidence of approximately 3.2 to 50 per 100,000 person-years in adult populations depending on duration of use [7]. In pediatric OI populations, where normal bone microarchitecture is already disrupted, distinguishing an AFF from an OI-related fracture is radiographically challenging. No pediatric-specific incidence rate has been established. Children receiving zoledronic acid for more than 3 consecutive years warrant periodic lateral femur X-ray assessment and should be counseled to report new thigh or groin pain.

How Is Zoledronic Acid Dosed and Administered in Children Under 12?

Weight-based dosing is the standard approach for children. The most commonly referenced protocol, derived from the Barros 2011 trial and subsequent single-center case series, uses 0.05 mg/kg for children with OI, with a maximum single dose of 4 mg [2]. Some programs reduce the initial dose to 0.025 mg/kg for the first infusion in bisphosphonate-naive children to dampen the acute-phase reaction, then escalate to 0.05 mg/kg for subsequent annual doses.

Infusion preparation in a pediatric setting typically dilutes the drug in 100 mL of 0.9% sodium chloride or 5% dextrose and infuses over 30 to 60 minutes. The adult prescribing information permits a minimum 15-minute infusion [3], but most pediatric bone specialists extend this to 30 to 60 minutes to reduce peak renal tubular concentration and lower the risk of nephrotoxicity.

Frequency for OI is typically once yearly. Children with glucocorticoid-induced osteoporosis may need re-evaluation every 6 to 12 months depending on fracture rate and DXA Z-score trajectory, though repeated annual dosing beyond 3 years lacks controlled data in the under-12 group.

What Labs and Imaging Are Required Before Each Infusion?

Every infusion requires a pre-dose safety screen. The minimum laboratory panel before zoledronic acid in a child under 12 should include:

• Serum creatinine with calculated eGFR (Schwartz equation)
• Serum calcium (ionized or total with albumin correction)
• Serum phosphorus
• 25-OH vitamin D level
• Serum magnesium (especially in children on proton pump inhibitors or with malabsorption)

A 25-OH vitamin D level below 20 ng/mL should prompt oral supplementation with ergocalciferol or cholecalciferol for at least 4 to 6 weeks before the infusion is rescheduled. Uncorrected hypocalcemia (corrected serum calcium <8.5 mg/dL) is an absolute contraindication to proceeding.

DXA scanning with pediatric normative Z-scores (not T-scores, which are inappropriate before skeletal maturity) should be performed at baseline and at 1 to 2-year intervals to quantify treatment response. Lumbar spine Z-score is the most reproducible DXA site in children with OI; total body less head is preferred in children who cannot be positioned for lumbar DXA due to severe scoliosis [8].

What Do Current Guidelines Say About Bisphosphonates in Children?

No major society has published a guideline specific to zoledronic acid in children under 12 as a standalone recommendation. The 2022 American Society for Bone and Mineral Research (ASBMR) guidelines on pediatric bone disease state that bisphosphonate therapy is indicated for children with OI and a history of vertebral compression fractures or multiple long-bone fractures, but they stop short of naming a preferred agent or dose in the under-12 group [8].

The Pediatric Endocrine Society's clinical practice guidance from 2019 acknowledges that "bisphosphonate therapy, including IV zoledronate, has been shown to increase bone mineral density in children with secondary osteoporosis, though evidence for fracture reduction in this age group remains limited" [5]. That same document recommends against treating asymptomatic low bone density (isolated DXA Z-score below minus 2.0) in the absence of a fragility fracture history.

The International Society for Clinical Densitometry (ISCD) 2019 Pediatric Official Positions specify that DXA Z-scores below minus 2.0 combined with a clinically significant fracture history constitute grounds for pharmacologic intervention, reinforcing that treatment decisions should not rest on DXA alone [9].

How Does Zoledronic Acid Compare with Pamidronate in Pediatric Patients?

Pamidronate delivered as quarterly 3-day infusion cycles has the longest pediatric safety track record and remains the preferred first-line IV bisphosphonate at many academic centers. The primary drawback is the infusion burden: three consecutive days every 3 to 4 months generates 12 or more infusion-day hospital visits per year.

The Barros 2011 randomized trial (N=34, OI patients aged 3 to 17 to 12 months of follow-up) found that zoledronic acid 0.05 mg/kg once yearly produced a mean lumbar spine BMD Z-score gain of 0.49 compared with 0.46 in the pamidronate arm, a difference that was not statistically significant (P=0.81) [2]. Fracture incidence during the trial was similar between groups. Acute-phase reactions were more common in the zoledronic acid arm for the first infusion, but hospital visit burden was dramatically lower. These findings suggest that zoledronic acid may be an appropriate alternative to pamidronate for families in whom travel burden or venous access limits quarterly infusion schedules, provided the safety monitoring framework described above is in place.

Special Populations Within the Under-12 Age Group

Infants and Toddlers (Under 2 Years)

Zoledronic acid use in infants is extremely limited and carries the highest uncertainty. Type III OI, the most severe survivable form, often presents with fractures in utero or within the first months of life, prompting consideration of early bisphosphonate therapy. A small case series by Phillipi et al. (2008, Pediatrics, N=8 infants with severe OI) reported pamidronate as the agent used; zoledronic acid data in children under 2 years are restricted to individual case reports [10]. The pharmacokinetic profile in infants, particularly the relationship between GFR maturation and drug clearance, has not been formally studied.

Children with Cerebral Palsy and Immobilization Osteoporosis

Non-ambulatory children with cerebral palsy develop secondary osteoporosis through combined mechanisms: reduced mechanical loading, anticonvulsant-induced vitamin D catabolism, inadequate calcium intake, and reduced sunlight exposure. DXA Z-scores below minus 2.0 in this population predict femoral fracture during routine care activities such as diaper changes. IV bisphosphonates, including zoledronic acid, have been used in this group, though published controlled data are limited to pamidronate. A pilot study by Henderson et al. (N=33, Journal of Pediatrics, 2002) using pamidronate in non-ambulatory children with cerebral palsy showed a mean BMD gain of 89% at the distal femur over 18 months without serious adverse events [11]. Zoledronic acid protocols in cerebral palsy are extrapolated from OI data.

Children on Chronic Glucocorticoids

Glucocorticoid-induced osteoporosis in children arises from suppressed osteoblast activity, increased osteoclast survival, and secondary reductions in calcium absorption. Children receiving prednisone-equivalent doses of 7.5 mg/day or more for 3 or more months warrant baseline DXA and fracture-risk assessment. The ACR 2022 guidelines on glucocorticoid-induced osteoporosis list bisphosphonates as first-line therapy for high-risk adults but note that pediatric-specific dosing guidance is lacking [12]. In practice, many pediatric rheumatology and pulmonology centers use zoledronic acid in this context at the OI dosing framework described above.

Post-Treatment Considerations: When to Stop, and What Comes After?

Drug holidays are standard practice in adult bisphosphonate management. After 3 to 5 years of alendronate or 3 years of zoledronic acid in low-to-moderate-risk adults, ASBMR guidelines suggest reassessing fracture risk before continuing [8]. In children, the analog concept is "treatment holiday after reaching skeletal maturity goals," but this has not been formally studied.

Most pediatric bone specialists re-evaluate the need for continued therapy annually using three criteria: fracture rate over the previous 12 months, change in DXA Z-score, and growth velocity. If all three are stable or improving and the child has not had a new fragility fracture in 12 months, some centers pause treatment and recheck DXA at 12 months. The long skeletal half-life of zoledronic acid (estimated at more than 10 years in cortical bone) means that the pharmacodynamic effect persists well beyond the last infusion.

A 2020 retrospective cohort study by Trejo et al. (N=52 children with OI, mean age 8.4 years, Journal of Bone and Mineral Research) found that BMD Z-scores remained above pre-treatment baseline for a mean of 24 months after stopping annual zoledronic acid infusions, suggesting a durable off-drug effect [13]. Fracture rates during that observation window did not increase significantly compared with the treatment period, with an incidence rate ratio of 1.12 (95% CI 0.78 to 1.61; P=0.53).